Journal article
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
British journal of haematology, Vol.202(2), pp.248-255
07/2023
DOI: 10.1111/bjh.18828
PMID: 37129856
Abstract
The use of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD) is not well studied. We conducted a multicentre, retrospective analysis of adults with relapsed/refractory SOT-associated PTLD. Among 22 relapsed/refractory SOT-PTLD patients, the pathology was monomorphic B cell. Prior SOTs included 14 kidney (64%), three liver (14%), two heart (9%), one intestinal (5%), one lung (5%), and one pancreas after kidney transplant (5%). The median time from SOT to PTLD diagnosis was 107 months. Pre-CAR-T bridging therapy was used in 55% of patients, and immunosuppression was stopped completely before CAR-T infusion in 64%. Eighteen (82%) patients experienced cytokine release syndrome: one (5%) each grade (G) 3 and G4. The immune effector cell-associated neurotoxicity syndrome was observed in 16 (73%) patients: six (27%) G3 and two (9%) G4. The overall response rate was 64% (55% complete response). Three patients (14%) experienced allograft rejection after CAR-T. The two-year progression-free survival and overall survival rates were 35% and 58%, respectively. Additionally, the achievement of CR post-CAR-T was strongly associated with survival. Collectively, the safety and efficacy of CD19 CAR-T therapy in relapsed/refractory SOT-related PTLD appeared similar to pivotal CAR-T data, including approximately one-third of patients achieving sustained remission.
Details
- Title: Subtitle
- Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
- Creators
- Marshall McKenna - Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USANarendranath Epperla - The Ohio State UniversityArmin Ghobadi - Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USAJieqi Liu - Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USAAleksandr Lazaryan - Moffitt Cancer CenterUroosa Ibrahim - Department of Hematology and Oncology, Bone Marrow Transplantation and Cellular Therapy Program, Mount Sinai Hospital, New York, New York, USACaron A Jacobson - Harvard Medical SchoolSeema G Naik - Pennsylvania State UniversityLoretta Nastoupil - The University of Texas MD Anderson Cancer CenterSayan Mullick Chowdhury - The Ohio State UniversityTimothy J Voorhees - The Ohio State UniversityMiriam T Jacobs - Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USAUmar Farooq - Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospital and Clinics, Iowa City, Iowa, USAKeren Osman - Department of Hematology and Oncology, Bone Marrow Transplantation and Cellular Therapy Program, Mount Sinai Hospital, New York, New York, USAAdam J Olszewski - Brown UniversitySairah Ahmed - The University of Texas MD Anderson Cancer CenterAndrew M Evens - Rutgers, The State University of New Jersey
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.202(2), pp.248-255
- DOI
- 10.1111/bjh.18828
- PMID
- 37129856
- NLM abbreviation
- Br J Haematol
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Language
- English
- Electronic publication date
- 05/02/2023
- Date published
- 07/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984399484002771
Metrics
10 Record Views